Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14498591 | 0.88 | TSHR (0.39) | CYP2C9GRIN1GRIN2B | |
| SCHEMBL3456353 | 0.87 | PTGDR2 (0.39) | PTGDR2CXCR2GRIN1GRIN2BCMA1 | |
| SCHEMBL3456716 | 0.86 | PTGDR2 (0.39) | PTGDR2CXCR2 | |
| SCHEMBL3456552 | 0.82 | ALDH1A1 (0.39) | PTGDR2CXCR2HDAC6 | |
| SCHEMBL3456655 | 0.80 | ADORA1 (0.43) | PTGDR2CXCR2HDAC6 | |
| SCHEMBL2804576 | 0.79 | CYP2C9 (0.40) | PTGDR2CYP2C9 | |
| SCHEMBL3455950 | 0.79 | PTGDR2 (0.40) | PTGDR2 | |
| SCHEMBL3462977 | 0.79 | CXCR2 (0.36) | PTGDR2CYP2C9CXCR2HDAC6 | |
| SCHEMBL3456383 | 0.77 | GLA (0.46) | PTGDR2 | |
| SCHEMBL14498582 | 0.76 | TSHR (0.41) | CYP2C9GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLA2G7, PLA2G4B | PTGDR2 167/4885CYP2C9 1138/4885PTGDR 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.